FOXO3 Working Group
Project Leader: Arnie Kahn, PhD
California Pacific Medical Center, San Francisco
The transcription factor FOXO3 is among a small group of genes that has been associated with exceptional longevity in humans and, as such, is seen as starting point for developing therapeutics that will slow the aging process and lower the incidence and severity of age-related diseases. To the latter end, the working group is focused on establishing a translational research effort that will both provide better understanding of the functional genomics of the FOXO3 gene, particularly the genetic variants linked to longevity, and develop a research platform for screening of drugs, natural products and small molecules that will act on the gene or members of the FOXO3 pathway to promote healthy aging.
Arnie Kahn, PhD
akahn [AT] buckinstitute.org
APOE Working Group
Project Leader: Nalini Raghavachari, PhD
National Institute of Aging
Apolipoprotein E (ApoE) has consistently emerged as a determinant of health span associated with exceptional longevity, more prevalent among centenarians and decreased susceptibility to age related diseases. Based on available epidemiologic data, the ApoE2 isoform appears to have protective effects against various diseases (e.g., AD, CVD). The purpose of the ApoE 2 working group is to identify projects (through secondary data analysis of existing genotypic and phenotypic data and preliminary in vitro studies or in experimental models) which would help to clarify the pathways by which ApoE2 may exert the protective effects and to identify druggable targets (i.e. mimic ApoE 2 effects).
Nalini Raghavachari, PhD
nraghavachari [AT] mail.nih.gov